๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
NCT07469267Breast Cancer, Radiotherapy
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer๏ผˆNSCLC๏ผ‰ Patients
NCT07171606First-line Advanced NSCLC Patients
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2
240
Shanghai
2025-10-24
Recruiting
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
NCT07263386Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
460
Nanjing
2025-10-23
Recruiting
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
NCT07091305Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy, Consolidation Immunotherapy
Shanghai Chest Hospital
Phase 2
28
Shanghai
2025-10-23
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
JSKN022 in Subjects With Advanced Malignant Solid Tumors
NCT07292402Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
225
Guangzhou
2025-10-23
Active, closed
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
NCT07196774Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
740
Shenyang, Shanghai
2025-10-23
Recruiting
FARAPULSEโ„ข Pulsed Field Ablation System
NCT06762717Paroxysmal AF
Boston Scientific Corporation
Observational
500
Beijing
2025-10-23
Recruiting
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
NCT07053072Liver Cancer
West China Hospital
Phase 1
9
Chengdu
2025-10-23
Active, closed
A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine ๏ผˆCHO Cell๏ผ‰, LYB004 in Adults Aged 40 Years and Older
NCT07311148Herpes Zoster (HZ), Shingles, VZV, Recombinant Zoster Vaccine
Guangzhou Patronus Biotech Co., Ltd.
Phase 2
840
Hengyang
2025-10-23
Recruiting
Neuroprotection Bundles For Comatose Survivors Following Cardiac Arrest
NCT06992843Cardiac Arrest, Post-cardiac Arrest Care
Xiangya Hospital of Central South University
Not applicable
1,008
Changsha
2025-10-22
Recruiting
A Study of AK138D1 in Advanced Malignant Tumors
NCT07281326Solid Cancer
Akeso
Phase 1
200
Harbin
2025-10-22
Recruiting
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
NCT07297576ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia, MDS (Myelodysplastic Syndrome)
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
36
Tianjing
2025-10-22
Recruiting
The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic Amenorrhea
NCT07580950Functional Hypothalamic Amenorrhea
Peking Union Medical College Hospital
Phase 4
210
Beijing
2025-10-22
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Active, closed
Development of a Pan-Cancer Screening Model Based on Blood Biomarkers
NCT07554157Neoplasms
Zhejiang Cancer Hospital
Observational
10,000,000
Hangzhou
2025-10-22
Recruiting
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
NCT07272434Respiratory Syncytial Virus (RSV)
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
NCT07179484Gastroesophageal Junction Adenocarcinoma
Beijing GoBroad Hospital
Observational
20
Beijing
2025-10-22
Recruiting
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
NCT07508852SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
Peking University First Hospital
Phase 1/2
30
Beijing
2025-10-22
Recruiting
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07170995Advanced or Metastatic Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
460
Jinan
2025-10-22
Recruiting
A Multicenter, Prospective, Randomized Controlled Study on EUS-Guided Precise Disconnection of Varices Versus Endoscopic Gastric Variceal Glue Injection for the Prevention of Gastric Variceal Bleeding.
NCT07532915Gastric Variceal
Nanfang Hospital, Southern Medical University
Not applicable
84
Guangzhou
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
NCT07208136Advanced Solid Tumors
Jemincare
Phase 1
102
Beijing
2025-10-22
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
Shanghai
2025-10-22
Recruiting
Distribution Characteristics of Helicobacter Pylori
NCT07253948Helicobacter Pylori, Early Gastric Cancer
Jilin University
Observational
231
Changchun
2025-10-22
Recruiting
Complex Arrhythmia Registry
NCT07024927Atrial Fibrillation (AF), Ventricular Tachycardia (VT)
Beijing Anzhen Hospital
Observational
4,000
Beijing
2025-10-21
Not yet open
Development and Validation of a Risk Prediction Model for Ischemic Stroke in Acute Myocardial Infarction Without Comorbid Atrial Fibrillation
NCT07171892Myocardial Infarction
First Affiliated Hospital of Ningbo University
Observational
4,000
Ningbo
2025-10-21
Recruiting
Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects
NCT07301203Healthy, Healthy Participants
Beijing Tide Pharmaceutical Co., Ltd
Phase 1
90
Beijing
2025-10-21
Recruiting
Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
NCT06987305Stroke, Acute Ischemic
Xinqiao Hospital of Chongqing
Phase 3
820
Wuhan, Xiangtan, Jiujiang, Nanchang
2025-10-21
Active, closed
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
NCT07208461Respiratory Syncytial Virus Infection Prevention
Guangzhou Patronus Biotech Co., Ltd.
Phase 2
700
Dangyang
2025-10-21
Recruiting
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
NCT07239973Healthy, Non-diabetic Overweight or Obese
BrightGene Bio-Medical Technology Co., Ltd.
Phase 1
75
Kunming
2025-10-21
Recruiting
Awareness, Knowledge and Behavioral Seeking of Gynaecological Problems
NCT07208383Gynecologic Disease
Chinese University of Hong Kong
Observational
800
Hong Kong
2025-10-21
Recruiting
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
NCT07257653Colorectal Neoplasms, RAS, BRAF, Cetuximabฮฒ
Zhejiang University
Phase 2
70
Hangzhou
2025-10-21
Recruiting
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak
NCT07209787Rectal Cancer
Beijing Chao Yang Hospital
Phase 4
966
Beijing
2025-10-21
Recruiting
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
NCT07259590Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
126
Beijing, Guangzhou, Zhengzhou, Wuhan
2025-10-21
Recruiting
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
NCT07234591Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Usynova Pharmaceuticals Ltd.
Not applicable
140
Shanghai
2025-10-21
Active, closed
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
NCT07185776Lipoprotein Disorder
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
203
Xiโ€™an
2025-10-21
Not yet open
Multi-omics Study of Peritoneal Dialysis Effluent to Explore Biomarkers of Peritoneal Fibrosis
NCT07208513Peritoneal Dialysis, Peritoneal Fibrosis
Shanghai Jiao Tong University School of Medicine
Observational
55
Shanghai
2025-10-20
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
NCT07111546Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Recruiting
Evaluation of the Clinical Outcomes of the Embolic Protection System in Preventing Distal Embolism During Femoropopliteal Debulking Procedures
NCT07282301Femoropopliteal Disease
RenJi Hospital
Observational
150
Shanghai
2025-10-20
Recruiting
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
NCT07775820Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou, Shenzhen, Nanchang, Wenzhou
2025-10-20
Recruiting
Surgical Total Clearance Versus Extrahepatic Bile Duct Preservation for Biliary Tract Malignancies: A Single-Center, Randomized, Two-Arm, Prospective Phase II Clinical Trial
NCT07609641BTC
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2025-10-20
Recruiting
Haplo-Cord HSCT for AML/MDS
NCT07588360MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital
Not applicable
82
Fuzhou, Guangzhou, Chengdu, Beijing
2025-10-20
Recruiting
Comparison of Underdilated Versus Standard TIPS in Preventing Variceal Rebleeding in Patients With Cirrhosis
NCT07253389Liver Cirrhosis, Gastroesophageal Varices Bleeding
Air Force Military Medical University, China
Not applicable
648
Xi'an
2025-10-20
Recruiting
The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.
NCT07335536Hypoxia, Infertility, Infertility Assisted Reproductive Technology
Diansan Su
Not applicable
400
Dongyang, Hangzhou, Lishui
2025-10-20
By invitation
A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia
NCT07521683Schizophrenia(Acute)
NeuShen Therapeutics
Phase 2
150
Shanghai
2025-10-20
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Recruiting
Personalized iTBS in Real-World Clinical Settings for Schizophrenia
NCT07176468Schizophrenia, Transcranial Magnetic Stimulation
Anhui Medical University
Not applicable
40
Hefei
2025-10-20
Recruiting
Risk Factors Affecting MSC Efficacy in ACLF Patients
NCT07198854Acute-On-Chronic Liver Failure
Sun Yat-sen University
Observational
446
Guangzhou
2025-10-20
Recruiting
Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease
NCT07157345Parkinson Disease (PD)
Ruijin Hospital
Phase 1
12
Shanghai
2025-10-20
Recruiting
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
NCT07104604Rectal Cancer
Affiliated Cancer Hospital of Shantou University Medical College
Phase 2
51
Shantou
2025-10-20
Recruiting
Association of Biomarkers and Gastric Antral Motility Index With Feeding Intolerance in Critically Ill Patients
NCT07178626Critically Ill Patients Who Are Not Allowed to Eat Orally But Can Initiate Enteral Nutrition Within 48 Hours of ICU
The First Hospital of Jilin University
Observational
160
Changchun
2025-10-20
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
1,196
Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing
2025-10-20
Recruiting
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
NCT07668453Biliary Tract Neoplasms
The First Affiliated Hospital with Nanjing Medical University
Phase 2
30
Nanjing
2025-10-20
Recruiting
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
NCT07285850HCC - Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2/3
20
Shanghai
2025-10-20
Active, closed
Multicenter Study to Develop a Model to Identify Uric Acid Urinary Tract Stones Using CT and Lab Tests
NCT07328932Urinary Tract Stones
Jian Zhuo
Observational
1,650
Shanghai
2025-10-20
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Active, closed
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
NCT07193147Diabetes
Gan & Lee Pharmaceuticals.
Phase 1
36
Linyi
2025-10-20
Recruiting
A Sitting Tai Chi Programme for Chronic Stroke Survivors With Post-stroke Cognitive Impairment
NCT07512739Stroke, Cognitive Impairment
Chinese University of Hong Kong
Not applicable
176
Kunming
2025-10-20
Recruiting
The Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia
NCT07208357Fibromyalgia, Pregabalin, Duloxetine, Pain
Beijing Tiantan Hospital
Not applicable
384
Beijing
2025-10-20
Recruiting
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
NCT07585981IgA Glomerulonephritis
Chinese PLA General Hospital
Observational
30
Beijing
2025-10-20
Recruiting
A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT
NCT07602569Cancer (With or Without Metastasis)
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Observational
110
Guangzhou
2025-10-20
By invitation
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects
NCT07384104Osteoporosis
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 1
118
Hefei
2025-10-19
Recruiting
A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT07165223Diabetes
Gan & Lee Pharmaceuticals.
Phase 3
300
Linyi
2025-10-17
By invitation
An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
NCT07503028T1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes Mellitus
Celregen Therapeutics
Phase EARLY_PHASE1
10
Hefei
2025-10-17
Recruiting
A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
NCT07229950Adult Patients With Moderately to Severely Active Ulcerative Colitis
Shandong Suncadia Medicine Co., Ltd.
Phase 2
48
Chengdu
2025-10-17
Recruiting
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
NCT07206498Non Small Cell Lung Cancer (NSCLC)
Wayshine Biopharm, Inc.
Phase 1/2
48
Shanghai
2025-10-17
Recruiting
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
NCT07168200Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 3
720
Shanghai
2025-10-17
Recruiting
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression
NCT05465252Age-Related Macular Degeneration
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
24
Shanghai
2025-10-17
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839AML, IDH1 Mutation, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
23
Tianjin
2025-10-17
Recruiting
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
NCT07101744Nasopharyngeal Carcinoma (NPC), First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
41
Guangdong
2025-10-17
Active, closed
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenstrรถm Macroglobulinemia
NCT07169331Waldenstrรถm's Macroglobulinemia
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury
NCT07486804Non-suicidal Self-injury
Anhui Medical University
Not applicable
90
Hefei
2025-10-16
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors
NCT07351903Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 1
15
Tianjin
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors
NCT07231081Solid Tumors
Tcelltech Inc.
Phase 1
85
Beijing
2025-10-16
Active, closed
Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer
NCT07262671NSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University
Observational
100
Shanghai
2025-10-16
Recruiting
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
NCT07189949Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
120
Tianjin
2025-10-16
Recruiting
The Effect of Bifidobacterium Probiotics on Gut Microbiota Changes in Healthy Adults During Short-term Travel Along the Silk Road
NCT07182500Healthy Adult Volunteer
Universiti Sains Malaysia
Phase 2
75
Huangpu
2025-10-16
Recruiting
Construction of a Portal Hypertension Biobank
NCT07419724Variceal Bleeding, Portal Hypertension
Shanghai Zhongshan Hospital
Observational
1,000
Shanghai
2025-10-16
Recruiting
CS-121 APOC3 Base Editing in FCS
NCT07176923Familial Chylomicronemia Syndrome (FCS)
CorrectSequence Therapeutics Co., Ltd
Phase EARLY_PHASE1
15
Hefei
2025-10-15
Recruiting
Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy
NCT07209345Post-craniotomy, Pain
Beijing Tiantan Hospital
Not applicable
216
Beijing
2025-10-15
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Not yet open
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
NCT07207681Advanced Solid Tumors
The First Hospital of Jilin University
Phase 1
30
Changchun
2025-10-15
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals
Phase 1/2
188
Beijing
2025-10-15
Recruiting
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
NCT07077434Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Recruiting
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
NCT07150962Overweight or Obesity
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
168
Hefei
2025-10-15
Not yet open
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2
104
Shanghai
2025-10-15
Recruiting
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
NCT07160725Solid Tumours
Bristol-Myers Squibb
Phase 1/2
540
Guangzhou
2025-10-15
Recruiting
The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors
NCT07159048Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis
Fudan University
Not applicable
120
Shanghai
2025-10-15
Not yet open
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
NCT07152769Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2
104
Shanghai
2025-10-15
Active, closed
Fertility Decision and Outcomes in Young Women With Breast Cancer
NCT07804745Breast Cancer - Female, Fertility
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Changchun, Hangzhou
2025-10-15
Recruiting
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
NCT07229768Pancreatic Cancer
Yan Xing
Phase EARLY_PHASE1
4
Shanghai
2025-10-15
Not yet open
Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer
NCT07170982Endometrial Cancer
Sun Yat-sen University
Phase 2
128
Guangzhou
2025-10-15
Recruiting
Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma
NCT07240454Chronic Subdural Hematoma
Tao Liu
Not applicable
143
Beijing, Tianjin
2025-10-15
Recruiting
Integrated Clinical Study of Traditional Chinese and Western Medicine for Refractory Rheumatoid Arthritis
NCT07721142Rheumatoid Arthritis (RA)
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
Phase 4
300
Shanghai
2025-10-15
Recruiting
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
NCT07447570Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2025-10-15
Rows per page Showing 5601–5700 of 19052
Previous 55 56 57 58 59 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=57

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.